Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
BHVN
Strong SellHot AirBiohaven Ltd. · Healthcare · United States · $2.3B · Avg Vol: $40M/d
COMPANY DESCRIPTION
Biohaven Ltd. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for rare diseases, with a particular focus on central nervous system (CNS) disorders. Formed from the spin-off of certain assets after Pfizer's acquisition of its predecessor, the company retains a pipeline of early to mid-stage candidates. BHVN aims to address significant unmet medical needs in niche neuropsychiatric and neurodegenerative conditions by leveraging established scientific expertise.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | 25.0M | 30.0M | — |
| EPS | -5.77 | -5.73 | -9.28 | -6.86 | — | -4.55 | -2.64 | -1.99 | — |
| Shares | 150.6M | 81.1M | 101.2M | 132.8M | -11.8% | 151.0M | — | — | — |
| Debt | 33.6M | 30.9M | 36.6M | 284.6M | 103.8% | 297.0M | — | — | — |
| Equity | 538.8M | 428.0M | 423.4M | 52.1M | -54.1% | — | — | — | — |
| Op CF | -297.7M | -331.7M | -582.5M | -609.4M | — | -511.4M | — | — | — |
| Inv CF | -304.8M | 129.8M | -245.0M | 300.6M | — | — | — | — | — |
| Fin CF | 767.6M | 211.9M | 677.8M | 439.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BHVN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BHVN | Biohaven Ltd.(you) | $2.3B | 18 | Strong Sell |
| OCUL | Ocular Therapeutix, Inc. | $2.3B | 18 | Strong Sell |
| RAPP | Rapport Therapeutics, Inc. | $2.3B | 19 | Strong Sell |
| PVLA | Palvella Therapeutics, Inc. | $2.2B | 16 | Strong Sell |
| MLYS | Mineralys Therapeutics, Inc. | $2.3B | 14 | Strong Sell |
| ZBIO | Zenas BioPharma, Inc. | $2.0B | 15 | Strong Sell |
| KOD | Kodiak Sciences Inc. | $2.4B | 12 | Strong Sell |
| NKTR | Nektar Therapeutics | $2.5B | 23 | Sell |
| STOK | Stoke Therapeutics, Inc. | $2.0B | 13 | Strong Sell |
| DMRA | Damora Therapeutics, Inc. | $1.8B | 20 | Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%